Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
暂无分享,去创建一个
C. Rowe | C. Masters | P. Maruff | C. Szoeke | D. Ames | S. Burnham | V. Villemagne | K. Ellis | P. Bourgeat | O. Salvado | B. Brown | Ralph M. Martins | S. Macaulay
[1] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[2] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[3] K. Blennow,et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[4] Olivier Salvado,et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.
[5] C. Jack,et al. An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease , 2012, Annals of neurology.
[6] C. Rowe,et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.
[7] E. Siemers,et al. Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid &bgr; Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease , 2012, Clinical neuropharmacology.
[8] Clifford R Jack,et al. Testing the Right Target and Right Drug at the Right Stage , 2011, Science Translational Medicine.
[9] Andrei G. Vlassenko,et al. Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.
[10] Victor L. Villemagne,et al. Brain Amyloid Imaging , 2011, The Journal of Nuclear Medicine.
[11] B. Strooper,et al. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.
[12] J. Morris,et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[13] Nick C Fox,et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[14] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[15] R. Pietrzak,et al. Intra-Individual Variability in Alzheimer's Disease and Cognitive Aging: Definitions, Context, and Effect Sizes , 2011, PloS one.
[16] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[17] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[18] C. Jack,et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.
[19] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[20] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[21] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[22] S Ourselin,et al. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.
[23] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[24] Charles D. Smith,et al. Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease , 2009, Neurobiology of Aging.
[25] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[26] Nick C Fox,et al. The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.
[27] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[28] Gina N. LaRossa,et al. [11C]PIB in a nondemented population , 2006, Neurology.
[29] E. Tangalos,et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.
[30] A. Toga,et al. The Alzheimer's disease neuroimaging initiative. , 2005, Neuroimaging clinics of North America.
[31] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[32] M Greiner,et al. A modified ROC analysis for the selection of cut-off values and the definition of intermediate results of serodiagnostic tests. , 1995, Journal of immunological methods.
[33] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[34] C. Rowe,et al. Rapid decline in episodic memory in healthy older adults with high amyloid-β. , 2013, Journal of Alzheimer's disease : JAD.
[35] E. Tangalos,et al. Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .
[36] H. Akaike,et al. Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .